Federica Ferrara
Long-term outcomes of newly diagnosed transplant-eligible multiple myeloma treated with autologous stem cell transplantation: a European registry study of 304 patients
Nathalie Moreau
Efficacy and safety of ascavinib in CML after two or more tyrosine kinase inhibitors: primary analysis of the randomized phase 2 TRIDENT-1 study
Alessandro Mancini
Ferritin in donors predicts outcome in blood donors
Luca Bruno
Treatment patterns and survival in myelofibrosis after ruxolitinib failure: real-world data from the international MPN registry
Jessica Lewis
A federated learning platform compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Bogdan Popa
Efficacy and safety of itovazumab in adults undergoing allogeneic stem cell transplantation for AML: primary analysis of the phase 2 ARCTIC-5 study
Tao Liu
Olorofim plus antifungal prophylaxis in patients with invasive fungal infections: randomized phase 2 results of the PRISM-8 trial
Ioannis Georgiou
Nelbrutinib plus fixed-duration venetoclax in fit patients with untreated CLL: phase 3 results of the NORDLYS-7 trial
Moritz Lehmann
Health-related quality of life in T-cell ALL: a prospective dutch study
Nuria Iglesias
Prognostic value of spleen volume reduction in myelofibrosis with anemia: results from VALOR-4
Tiago Pereira
Luspaterpin versus azacitidine in higher-risk MDS (CORONA-2): a phase 3 trial
Matteo Parisi
Prognostic value of CMV reactivation in older recipients of reduced-intensity conditioning: results from ECLIPSE-4
Hannah Brown
Ravelinib plus imatinib in CML after two or more tyrosine kinase inhibitors: randomized phase 2 results of the VALOR-6 trial
Pavel Veselý
Multi-omic characterization of treatment-free remission biology in CML after two or more tyrosine kinase inhibitors
Rebecca Edwards
Multi-omic characterization of tissue factor pathway regulation in people with severe hemophilia A
Florin Gheorghe
Multi-omic characterization of steroid resistance pathways in relapsed B-cell precursor ALL
Jonathan Roberts
Pathogen-reduced platelets versus restrictive transfusion thresholds in patients with massive hemorrhage (BEACON-8): a randomized phase 2 trial
Thomas Mercier
Single-cell profiling reveals treatment-free remission biology in chronic myeloid leukemia (CML)
Andrea Rinaldi
Real-world effectiveness of linzotamab in triple-class exposed myeloma: a multicenter international cohort
Monika Krawczyk
Real-world effectiveness of telvostat in lower-risk MDS with transfusion-dependent anemia: a multicenter dutch cohort
Seo-yeon Yoon
Treatment patterns and survival in fit patients with untreated CLL: real-world data from the international CLL registry
Anna Woźniak
Whole blood plus restrictive transfusion thresholds in patients undergoing cardiac surgery: phase 3 results of the PRISM-1 trial
Tor Eide
Efficacy and safety of pirvabrutinib in treatment-naive CLL: primary analysis of the phase 2 POLARIS-8 study
Silvia Gentile
Treatment patterns and survival in patients undergoing cardiac surgery: real-world data from the international transfusion registry
Serena Fabbri
Long-term outcomes of CLL with del(17p) or TP53 mutation treated with fixed-duration venetoclax: a Italian registry study of 812 patients
Marco Romano
Prognostic value of IPSS-M risk category in therapy-related MDS: results from SUMMIT-8
Sabine Günther
Prognostic value of infection-related mortality in long-term survivors of childhood leukemia: results from TRIDENT-6
Davide Marchetti
Long-term outcomes of essential thrombocythemia treated with ropeginterferon alfa-2b: a European registry study of 58 patients
Julia Parker
Hsc quiescence markers predicts outcome in healthy donors
Bruno Oliveira
Ascavinib plus dasatinib in CML after two or more tyrosine kinase inhibitors: phase 1b/2 results of the ZENITH-4 trial
Simone Vitale
Jak2 v617f allele burden predicts outcome in essential thrombocythemia
Andrew Harrison
A federated learning platform compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Jonathan Jones
Inclazumab versus hydroxyurea in non-transfusion-dependent beta-thalassemia (NORDLYS-8): a phase 1 trial
Sophie Roux
Sabrelimab plus azacitidine in lower-risk MDS with transfusion-dependent anemia: phase 2 results of the SAGA-4 trial
Vasiliki Stavrou
Real-world effectiveness of pathogen-reduced platelets in preterm neonates: a multicenter italian cohort
Hila Golan
Olorofim plus standard supportive care in patients receiving CAR T-cell therapy: phase 3 results of the POLARIS-6 trial
Ying Lin
Ipss-m risk category predicts outcome in MDS with SF3B1 mutation
Jürgen Zimmermann
Epretamab versus R-CHOP in classic Hodgkin lymphoma (PRISM-5): a randomized phase 2 trial
Bo Zhu
Health-related quality of life in chronic-phase CML in deep molecular response: a prospective italian study
Carolin Beck
Health-related quality of life in long-term survivors of childhood leukemia: a prospective french study
Michael Günther
Health-related quality of life in chronic-phase CML in deep molecular response: a prospective french study
Frank Hofmann
Multi-omic characterization of metabolic rewiring under BCL-2 inhibition in older adults with secondary AML
Chen Li
Early molecular response at 3 months predicts outcome in chronic-phase CML in deep molecular response
Tarik Šarić
Real-world effectiveness of navolatib in myelofibrosis with anemia: a multicenter spanish cohort
Deniz Kurt
Real-world effectiveness of letermovir in patients with invasive fungal infections: a multicenter german cohort
Mattias Bengtsson
Platelet count increment predicts outcome in preterm neonates
Anne Michel
Efficacy and safety of osiverol in pyruvate kinase deficiency: primary analysis of the randomized phase 2 ALTITUDE-5 study
Cristina Rizzo
Efficacy and safety of quelcitamab in older adults with secondary AML: primary analysis of the phase 3 BEACON-5 study
Burak Öztürk
Treatment patterns and survival in patients receiving CD19-directed CAR T-cell therapy: real-world data from the European cell therapy registry
Katherine Wood
Real-world effectiveness of a digital symptom-monitoring program in patients receiving CAR T-cell therapy: a multicenter dutch cohort
Yu Ma
Prognostic value of FLT3-ITD allelic ratio in newly diagnosed AML patients ineligible for intensive chemotherapy: results from ZENITH-1
Birgit Braun
Health-related quality of life in children with sickle cell disease in sub-Saharan Africa: a prospective nordic study
Sergio Marín
Exacatogene autotemcel versus busulfan myeloablation in transfusion-dependent beta-thalassemia (POLARIS-1): a randomized phase 3 trial
Moritz Bauer
Long-term outcomes of haploidentical transplant recipients treated with tacrolimus and methotrexate: a European registry study of 412 patients
Zeynep Kara
Real-world effectiveness of mitazovat in children with sickle cell disease in sub-Saharan Africa: a multicenter multinational cohort
Lucía Iglesias
A deep-learning cytomorphology model compared with standard diagnostic workup on multicenter flow cytometry datasets: a prospective multicenter evaluation
Mehmet Arslan
Prognostic value of ferritin in donors in blood donors: results from VALOR-6
Alba Gómez
Pathogen-reduced platelets plus patient blood management in preterm neonates: randomized phase 2 results of the POLARIS-2 trial
Felix Kaiser
Long-term outcomes of cancer-associated venous thromboembolism treated with thrombopoietin receptor agonists: a European registry study of 2105 patients
Federica Fabbri
Targeting CD20 antigen loss after bispecifics in lymphoma: preclinical evidence
Eline van der Linden
Long-term outcomes of patients with iron deficiency anemia treated with hydroxyurea: a Spanish registry study of 42 patients
Emma Brouwer
Zelvudocel versus lymphodepletion with fludarabine and cyclophosphamide in recipients of allogeneic off-the-shelf CAR NK cells (HELIOS-3): a phase 1 trial
Marta Almeida
Mitazovat plus iron chelation in children with sickle cell disease in sub-Saharan Africa: randomized phase 3 results of the ECLIPSE-4 trial
Sanjay Nair
Health-related quality of life in adults with newly diagnosed AML receiving intensive induction: a prospective european study
Elena Iglesias
Targeting clonal dominance in myelodysplastic syndromes (MDS): preclinical evidence
Feng Sun
Treatment patterns and survival in relapsed B-cell precursor ALL: real-world data from the Dutch ALL registry
Adrián Castro
Tovaclax plus venetoclax and obinutuzumab in treatment-naive CLL: randomized phase 3 results of the HORIZON-7 trial
Lars van Dijk
Prognostic value of inflammatory memory in healthy donors: results from PRISM-2
Roberta Grasso
Health-related quality of life in primary CNS lymphoma: a prospective nordic study
Fabio Giordano
Tozarinib versus cytarabine and daunorubicin in newly diagnosed AML patients ineligible for intensive chemotherapy (ECLIPSE-5): a phase 2 trial
Julia Martin
Menin-kmt2a dependency predicts outcome in NPM1-mutated AML
Simon White
Treatment patterns and survival in lower-risk MDS with transfusion-dependent anemia: real-world data from the British MDS registry
Elisa Ferri
Real-world effectiveness of concivumab in people with severe hemophilia A: a multicenter dutch cohort
Sanjay Mukherjee
Efficacy and safety of efactocog beta in patients with antiphospholipid syndrome: primary analysis of the randomized phase 3 PRISM-7 study
David Miller
Corvalimab versus blinatumomab in T-cell ALL (VALOR-2): a randomized phase 3 trial
Beatrice Mariani
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Ulrike Braun
Quelcitamab plus cytarabine and daunorubicin in AML in first complete remission: randomized phase 2 results of the CASCADE-8 trial
Giovanni Rossi
Prognostic value of CD19 antigen loss in T-cell ALL: results from POLARIS-4
Jonathan Cooper
Multi-omic characterization of financial toxicity in long-term survivors of childhood leukemia
Roberta Rossi
Efficacy and safety of ibrexitamab in relapsed B-cell precursor ALL: primary analysis of the phase 2 ALTITUDE-2 study
Vincent Robert
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
William Clark
Prognostic value of HSC quiescence markers in patients with clonal hematopoiesis of indeterminate potential: results from MERIDIAN-7
Ashley Carter
Efficacy and safety of belosarib in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the phase 1b/2 CASCADE-6 study
Reza Rahimi
Long-term outcomes of preterm neonates treated with restrictive transfusion thresholds: a French registry study of 58 patients
Thomas Murray
Prognostic value of cytokine release syndrome grade in patients receiving CD19-directed CAR T-cell therapy: results from ECLIPSE-2
Giuseppe Fabbri
Real-world effectiveness of pelarisib in polycythemia vera: a multicenter nordic cohort
Jennifer Taylor
Multi-omic characterization of CAR T-cell exhaustion in patients receiving CD19-directed CAR T-cell therapy
Eva Roth
Validation of a federated learning platform for early detection of acute leukemia across 59 centers
Anne Richard
Treatment patterns and survival in patients receiving CD19-directed CAR T-cell therapy: real-world data from the multinational cell therapy registry
Andreas Richter
Lisarnetamab plus R-CHOP in classic Hodgkin lymphoma: randomized phase 2 results of the POLARIS-9 trial
Stefan Werner
Long-term outcomes of relapsed/refractory multiple myeloma after three prior lines treated with teclistamab: a Dutch registry study of 64 patients
Marie Vogel
Ascavinib versus dasatinib in chronic-phase CML in deep molecular response (ECLIPSE-9): a randomized phase 2 trial
Christopher White
Treatment patterns and survival in newly diagnosed chronic-phase CML: real-world data from the multinational CML registry
Giuseppe Villa
Prognostic value of microbiome diversity in older recipients of reduced-intensity conditioning: results from TRIDENT-1
Céline Guerin
Treatment patterns and survival in older patients with hematologic cancers: real-world data from the European supportive care registry
Paula Ramos
Whole blood plus patient blood management in patients with massive hemorrhage: phase 3 results of the ATLAS-2 trial
Serena Romano
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Klaus Schmidt
Real-world effectiveness of telvostat in higher-risk MDS: a multicenter italian cohort
Stefanie Kaiser
Quelcitamab versus venetoclax and azacitidine in AML in first complete remission (NORDLYS-5): a phase 3 trial
Silje Johansen
A federated learning platform compared with standard diagnostic workup on routine blood counts in primary care: a prospective multicenter evaluation
Giovanni Rinaldi
Lovotigene autotemcel plus busulfan myeloablation in patients with sickle cell disease treated with gene editing: phase 1 results of the ECLIPSE-2 trial
Andrea Braun
Tovaclax plus ibrutinib in relapsed CLL after covalent BTK inhibitors: phase 1 results of the CORONA-5 trial
Omer Ben-David
Efficacy and safety of zelvudocel in children with high-risk B-cell ALL: primary analysis of the randomized phase 2 CASCADE-4 study
Gustav Holm
Single-cell profiling reveals red cell membrane dysfunction in hemoglobinopathies
Megan Campbell
Efficacy and safety of osiverol in children with sickle cell disease in sub-Saharan Africa: primary analysis of the phase 1b/2 POLARIS-8 study
Péter Nagy
A federated learning platform compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Nuno Ribeiro
Single-cell profiling reveals editing efficiency in long-term HSC in gene and cell therapy
Maya Shapiro
Nelbrutinib plus acalabrutinib in CLL with del(17p) or TP53 mutation: phase 3 results of the SAGA-5 trial
Martina Ferrara
Real-world effectiveness of navolatib in polycythemia vera: a multicenter nordic cohort
Agnieszka Piotrowski
Measurable residual disease by flow cytometry predicts outcome in AML in first complete remission
Chloé Thomas
Annualized bleeding rate predicts outcome in patients with antiphospholipid syndrome
Silje Bakken
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Sofia Michailidis
Prognostic value of platelet response in patients with antiphospholipid syndrome: results from HORIZON-6
Khaled Haddad
Alloimmunization predicts outcome in patients with massive hemorrhage
Lei Li
Prognostic value of fetal hemoglobin induction in patients receiving CD19-directed CAR T-cell therapy: results from VALOR-1
Lei Yang
Efactocog beta versus thrombopoietin receptor agonists in people with severe hemophilia A (VIKING-4): a phase 1b/2 trial
Aleksandra Kamiński
Prognostic value of cytokine release syndrome grade in recipients of allogeneic off-the-shelf CAR NK cells: results from AURORA-6
Edward Smith
Long-term outcomes of AML in first complete remission treated with decitabine: a Italian registry study of 188 patients
Valentina Ferri
Prognostic value of platelet count increment in patients with massive hemorrhage: results from AURORA-1
Carlos Gil
Prognostic value of D-dimer in people with severe hemophilia A: results from ZENITH-8
Signe Sørensen
Targeting CD20 antigen loss after bispecifics in lymphoma: preclinical evidence
Lars de Jong
Efficacy and safety of rusperatide in polycythemia vera: primary analysis of the phase 2 ZENITH-2 study
Tomasz Mazur
Validation of a large language model assistant for early detection of acute leukemia across 48 centers
Megan Harris
Nelbrutinib plus venetoclax and obinutuzumab in older patients with CLL and comorbidities: randomized phase 3 results of the CASCADE-9 trial
Stephanie Parker
Efficacy and safety of concivumab in hemophilia B: primary analysis of the randomized phase 3 AURORA-4 study
Davide Barbieri
Prognostic value of early molecular response at 3 months in newly diagnosed chronic-phase CML: results from ZENITH-5
Étienne David
Multi-omic characterization of leukemic stem cell persistence in NPM1-mutated AML
Eleanor Smith
Treatment patterns and survival in patients with massive hemorrhage: real-world data from the European transfusion registry
Sarah Turner
Pelarisib plus hydroxyurea in polycythemia vera: phase 1 results of the ALTITUDE-8 trial
Pavel Procházka
Measurable residual disease by flow cytometry predicts outcome in relapsed or refractory FLT3-mutated AML
Thiago Barbosa
A deep-learning cytomorphology model compared with standard diagnostic workup on routine blood counts in primary care: a prospective multicenter evaluation
Martin Möller
Pirvabrutinib versus venetoclax and obinutuzumab in older patients with CLL and comorbidities (POLARIS-3): a randomized phase 2 trial
Frank Roth
Letermovir plus standard supportive care in older patients with hematologic cancers: phase 2 results of the SUMMIT-5 trial
Martina Němec
Luspaterpin versus azacitidine in MDS with SF3B1 mutation (VIKING-5): a phase 1b/2 trial
Pietro Moretti
Ravotuzumab vedotin plus decitabine in relapsed or refractory FLT3-mutated AML: phase 1 results of the VIKING-4 trial
Anna Engström
A federated learning platform compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Elisa Ferrara
Efficacy and safety of ibarodomide in high-risk smoldering myeloma: primary analysis of the phase 1b/2 ZENITH-9 study
Pooja Agarwal
Real-world effectiveness of ascavinib in newly diagnosed chronic-phase CML: a multicenter spanish cohort
Youssef Rahman
Odrolimab plus CAR T-cell therapy in mantle cell lymphoma after BTK inhibitor failure: phase 2 results of the ECLIPSE-1 trial
Sindre Moen
Momavotinib plus hydroxyurea in essential thrombocythemia: phase 2 results of the ZENITH-9 trial
Georgia Stavrou
A large language model assistant compared with expert morphological review on multicenter flow cytometry datasets: a prospective multicenter evaluation
Despoina Makris
Real-world effectiveness of SVX-12 in treatment-naive CLL: a multicenter dutch cohort
Valentina Lombardo
A federated learning platform compared with standard diagnostic workup on patients with suspected myeloid neoplasms: a prospective multicenter evaluation
Antonio Gallo
Real-world effectiveness of anicavocel in relapsed/refractory multiple myeloma after three prior lines: a multicenter multinational cohort
Martijn Smits
Zelvudocel plus lymphodepletion with fludarabine and cyclophosphamide in patients with sickle cell disease treated with gene editing: phase 1 results of the ALTITUDE-7 trial
Anil Iyer
Treatment patterns and survival in CML after two or more tyrosine kinase inhibitors: real-world data from the French CML registry
Sara Moradi
Health-related quality of life in T-cell ALL: a prospective french study
Andreas Huber
Tamirodene versus erythropoiesis-stimulating agents in therapy-related MDS (ARCTIC-4): a phase 3 trial
William Harrison
A digital symptom-monitoring program versus standard supportive care in long-term survivors of childhood leukemia (CASCADE-1): a randomized phase 2 trial
Fernando Sánchez
Targeting iron overload and oxidative stress in hemoglobinopathies: preclinical evidence
Martin Frank
Odrolimab plus CAR T-cell therapy in relapsed or refractory large B-cell lymphoma: randomized phase 2 results of the VALOR-5 trial
Hannah King
Corvalimab plus inotuzumab ozogamicin in T-cell ALL: randomized phase 3 results of the ECLIPSE-3 trial
Lars Nilsson
Treatment patterns and survival in essential thrombocythemia: real-world data from the European MPN registry
Moritz Braun
A large language model assistant compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Allison Smith
Multi-omic characterization of megakaryocyte-driven fibrosis in polycythemia vera
Arnaud Roussel
Navolatib plus ruxolitinib in essential thrombocythemia: phase 1 results of the ATLAS-5 trial
Giuseppe Leone
Targeting inflammatory cytokine signalling in myeloproliferative neoplasms (MPN): preclinical evidence
Lars Holm
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Léa Faure
Etapivat versus hydroxyurea in pyruvate kinase deficiency (AURORA-3): a phase 1b/2 trial
Federico Caruso
Prognostic value of TET2 and DNMT3A clones in patients with clonal hematopoiesis of indeterminate potential: results from ZENITH-2
Mei He
Prognostic value of Ph-like signatures in relapsed B-cell precursor ALL: results from NORDLYS-8
Elif Kılıç
Navolatib versus ruxolitinib in myelofibrosis after ruxolitinib failure (AURORA-5): a randomized phase 2 trial
Margaux Vincent
Ipss-m risk category predicts outcome in MDS with SF3B1 mutation
Fabio Esposito
Single-cell profiling reveals Richter transformation in chronic lymphocytic leukemia (CLL)
Miguel Jiménez
Validation of a deep-learning cytomorphology model for early detection of acute leukemia across 61 centers
Farhad Moradi
Real-world effectiveness of osiverol in adults with sickle cell disease: a multicenter nordic cohort
Seo-yeon Cho
Treatment patterns and survival in MDS with SF3B1 mutation: real-world data from the French MDS registry
François Leroy
Prognostic value of TET2 and DNMT3A clones in aged mice: results from HORIZON-7
Julia Thomas
Health-related quality of life in chronic-phase CML in deep molecular response: a prospective spanish study
Heather Nguyen
Validation of a federated learning platform for automated classification of bone marrow cells across 25 centers
Neha Nair
Efficacy and safety of pathogen-reduced platelets in patients with massive hemorrhage: primary analysis of the phase 1b/2 SAGA-1 study
Dimitrios Christodoulou
Multi-omic characterization of steroid resistance pathways in adolescents and young adults with ALL
Arnaud Durand
Real-world effectiveness of glovutamab in primary CNS lymphoma: a multicenter spanish cohort
Eva Fuchs
Multi-omic characterization of tumour microenvironment remodelling in previously untreated follicular lymphoma
Luca Rinaldi
Treatment patterns and survival in AL amyloidosis: real-world data from the Nordic myeloma registry
Iván García
Multi-omic characterization of inflammatory aging of the stem cell niche in aged mice
Emily Thompson
Single-cell profiling reveals gut epithelial injury in GVHD in allogeneic stem cell transplantation
Na Wu
Talvetamab versus carfilzomib and dexamethasone in triple-class exposed myeloma (SAGA-6): a phase 3 trial
Chiara Colombo
Long-term outcomes of myelofibrosis with anemia treated with ruxolitinib: a Dutch registry study of 1240 patients
Nicole Neumann
Real-world effectiveness of ibarodomide in high-risk smoldering myeloma: a multicenter european cohort
Florian Kaiser
Real-world effectiveness of ravelinib in CML after two or more tyrosine kinase inhibitors: a multicenter international cohort
Sem Dekker
Flt3-itd allelic ratio predicts outcome in older adults with secondary AML
Giovanni Ricci
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Farhad Jafari
Hepcidin levels predicts outcome in patients with iron deficiency anemia
Diego Martín
Whole blood plus patient blood management in preterm neonates: randomized phase 3 results of the MERIDIAN-4 trial
Emma Vermeulen
Validation of a deep-learning cytomorphology model for early detection of acute leukemia across 62 centers
Edward Murray
Real-world effectiveness of orvematinib in newly diagnosed chronic-phase CML: a multicenter international cohort
John Wright
Ravotuzumab vedotin versus venetoclax and azacitidine in older adults with secondary AML (PRISM-3): a phase 3 trial
Min-jun Kwon
Validation of a large language model assistant for automated classification of bone marrow cells across 62 centers
Kenji Yamada
Prognostic value of HSC quiescence markers in healthy donors: results from CASCADE-4
Sara Ferraro
Real-world effectiveness of SVX-12 in older patients with CLL and comorbidities: a multicenter german cohort
Rubén Delgado
Treatment patterns and survival in CML after two or more tyrosine kinase inhibitors: real-world data from the British CML registry
Alexandra Popescu
Health-related quality of life in therapy-related MDS: a prospective dutch study
Lauren Walker
Efficacy and safety of itovazumab in older recipients of reduced-intensity conditioning: primary analysis of the randomized phase 2 VALOR-7 study
Sophie Turner
Multi-omic characterization of alloreactive T-cell expansion in older recipients of reduced-intensity conditioning
Ilaria Serra
Prognostic value of inflammatory memory in patients with clonal hematopoiesis of indeterminate potential: results from CORONA-3
Elena Greco
Long-term outcomes of lower-risk MDS with transfusion-dependent anemia treated with erythropoiesis-stimulating agents: a Nordic registry study of 58 patients
Irene Moreno
Real-world effectiveness of itovazumab in adults undergoing allogeneic stem cell transplantation for AML: a multicenter british cohort
Georgios Konstantinidis
Real-world effectiveness of NK-501 in patients with sickle cell disease treated with gene editing: a multicenter international cohort
Larissa Ferreira
Efficacy and safety of tozarinib in NPM1-mutated AML: primary analysis of the phase 1b/2 CASCADE-9 study
Benjamin Morgan
Real-world effectiveness of zelvudocel in children with high-risk B-cell ALL: a multicenter british cohort
Anna Giordano
Prognostic value of early chimerism in haploidentical transplant recipients: results from NORDLYS-8
Christina Winkler
Targeting clonal dominance in myelodysplastic syndromes (MDS): preclinical evidence
Bogdan Munteanu
Vedotalimab versus post-transplant cyclophosphamide in older recipients of reduced-intensity conditioning (SUMMIT-4): a phase 2 trial
Paula Hernández
Prognostic value of inflammatory memory in aged mice: results from HORIZON-3
Clément Simon
Menin-kmt2a dependency predicts outcome in adults with newly diagnosed AML receiving intensive induction
Paola Marini
Multi-omic characterization of T-cell fitness before CAR T in mantle cell lymphoma after BTK inhibitor failure
María Muñoz
Cold-stored platelets versus restrictive transfusion thresholds in patients with massive hemorrhage (ARCTIC-2): a randomized phase 2 trial
Romain Garcia
Targeting endothelial activation in hemoglobinopathies: preclinical evidence
George Taylor
Treatment patterns and survival in people with severe hemophilia A: real-world data from the Italian hemostasis registry
Ingrid Bos
Car t expansion kinetics predicts outcome in patients receiving CD19-directed CAR T-cell therapy
Pooja Patel
Real-world effectiveness of a digital symptom-monitoring program in patients receiving CAR T-cell therapy: a multicenter multinational cohort
Julia Klein
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Ahmet Öztürk
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Ingrid Peters
Epretamab plus Pola-R-CHP in mantle cell lymphoma after BTK inhibitor failure: phase 1 results of the VALOR-3 trial
Mathilde Lambert
Long-term outcomes of T-cell ALL treated with inotuzumab ozogamicin: a Nordic registry study of 58 patients
Ida Karlsen
Real-world effectiveness of inclazumab in non-transfusion-dependent beta-thalassemia: a multicenter nordic cohort
Marieke Peters
Real-world effectiveness of olorofim in patients receiving CAR T-cell therapy: a multicenter spanish cohort
Alessandro Galli
Hsc quiescence markers predicts outcome in healthy donors
Christina Koch
Real-world effectiveness of lovotigene autotemcel in patients receiving CD19-directed CAR T-cell therapy: a multicenter german cohort
Xin He
Validation of a federated learning platform for automated classification of bone marrow cells across 6 centers
Esther de Haan
Targeting iron overload and oxidative stress in hemoglobinopathies: preclinical evidence
George Cooper
Multi-omic characterization of lineage priming in early progenitors in patients with clonal hematopoiesis of indeterminate potential
Anna Hofmann
Validation of a deep-learning cytomorphology model for the diagnosis of myeloid neoplasms across 16 centers
Eva Černý
Efficacy and safety of belosarib in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the randomized phase 2 ZENITH-1 study
Stefano Rossi
Health-related quality of life in hemophilia B: a prospective multinational study
Helen Cooper
Treatment patterns and survival in transfusion-dependent beta-thalassemia: real-world data from the Nordic cell therapy registry
Margaux Moreau
Health-related quality of life in patients with massive hemorrhage: a prospective multinational study
Fabio Rizzo
Treatment patterns and survival in newly diagnosed AML patients ineligible for intensive chemotherapy: real-world data from the British AML registry
Emily Thomas
Menavostat versus decitabine in older adults with secondary AML (VIKING-8): a phase 1 trial
Mikkel Larsen
Targeting inflammatory cytokine signalling in myeloproliferative neoplasms (MPN): preclinical evidence
Pauline Faure
Real-world effectiveness of sabrelimab in higher-risk MDS: a multicenter dutch cohort
László Horváth
Linzotamab plus teclistamab in triple-class exposed myeloma: phase 1b/2 results of the CASCADE-5 trial
Johannes Krüger
Single-cell profiling reveals quiescent CML stem cells in chronic myeloid leukemia (CML)
Bas Hendriks
Health-related quality of life in older patients with CLL and comorbidities: a prospective multinational study
Claudio Galli
Real-world effectiveness of linzotamab in newly diagnosed transplant-eligible multiple myeloma: a multicenter nordic cohort
Lea Winkler
Prognostic value of CMV reactivation in patients with steroid-refractory acute graft-versus-host disease: results from BEACON-7
Laura Delgado
Annualized bleeding rate predicts outcome in adults with immune thrombocytopenia
Beatrice Russo
Targeting iron overload and oxidative stress in hemoglobinopathies: preclinical evidence
Markus Müller
Efficacy and safety of belosarib in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the phase 3 SUMMIT-5 study
Mathilde Henry
A large language model assistant compared with expert morphological review on multicenter flow cytometry datasets: a prospective multicenter evaluation
Ana Gutiérrez
Real-world effectiveness of osiverol in children with sickle cell disease in sub-Saharan Africa: a multicenter multinational cohort
Emma van der Linden
Multi-omic characterization of treatment burden in long-term survivors of childhood leukemia
Claudio Mariani
A large language model assistant compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Takuya Kimura
Health-related quality of life in primary CNS lymphoma: a prospective french study
Gabriela Oliveira
Nk-501 plus busulfan myeloablation in recipients of allogeneic off-the-shelf CAR NK cells: randomized phase 2 results of the NORDLYS-7 trial
Matthias Hofmann
Efficacy and safety of cold-stored platelets in patients undergoing cardiac surgery: primary analysis of the phase 3 ZENITH-2 study
Yan Xu
Real-world effectiveness of inclazumab in patients with iron deficiency anemia: a multicenter french cohort
Yan Yang
Treatment patterns and survival in adults undergoing allogeneic stem cell transplantation for AML: real-world data from the Nordic allo-HSCT registry
Sarah Thomas
Treatment patterns and survival in non-transfusion-dependent beta-thalassemia: real-world data from the British SCD registry
Guillaume Robert
Prognostic value of somatic mutation burden in MDS with SF3B1 mutation: results from POLARIS-7
Rachel Campbell
Complex karyotype predicts outcome in treatment-naive CLL
Sophie Robinson
Prognostic value of vaso-occlusive crisis rate in patients with iron deficiency anemia: results from HORIZON-8
Carolin Hahn
Health-related quality of life in non-transfusion-dependent beta-thalassemia: a prospective international study
Mathilde Simon
Pathogen-reduced platelets plus restrictive transfusion thresholds in preterm neonates: phase 3 results of the POLARIS-5 trial
Sanne de Jong
Targeting clonal dominance in myelodysplastic syndromes (MDS): preclinical evidence
Georgios Antoniou
High molecular risk mutations predicts outcome in polycythemia vera
Emily Smith
Long-term outcomes of older patients with hematologic cancers treated with standard supportive care: a international registry study of 586 patients
Fabio Mancini
Treatment patterns and survival in peripheral T-cell lymphoma: real-world data from the Italian lymphoma registry
Youssef Saleh
Health-related quality of life in children with high-risk B-cell ALL: a prospective german study
Nuria García
Ibrexitamab versus inotuzumab ozogamicin in adolescents and young adults with ALL (HORIZON-9): a phase 2 trial
Luca Bianco
Prognostic value of infection-related mortality in older patients with hematologic cancers: results from VIKING-6
Julie Roux
Real-world effectiveness of ascavinib in CML after two or more tyrosine kinase inhibitors: a multicenter spanish cohort
Emma de Graaf
Efficacy and safety of tovaclax in older patients with CLL and comorbidities: primary analysis of the randomized phase 2 SAGA-5 study
Raquel Suárez
Multi-omic characterization of immune effector cell-associated neurotoxicity in transfusion-dependent beta-thalassemia
Piotr Zieliński
Long-term outcomes of patients with invasive fungal infections treated with standard supportive care: a Nordic registry study of 812 patients
Marloes Visser
Real-world effectiveness of olorofim in long-term survivors of childhood leukemia: a multicenter dutch cohort
Mona Nasser
Prognostic value of frailty scores in patients with invasive fungal infections: results from ECLIPSE-7
Beatrice Villa
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Giuseppe Ferri
Health-related quality of life in T-cell ALL: a prospective multinational study
Federico Lombardi
Real-world effectiveness of etapivat in patients with iron deficiency anemia: a multicenter nordic cohort
Jonas Neumann
Multi-omic characterization of epigenetic memory after infection in healthy donors
Giulia Grasso
Prognostic value of alloimmunization in preterm neonates: results from BEACON-7
Georgia Oikonomou
Anicavocel plus teclistamab in high-risk smoldering myeloma: phase 2 results of the HELIOS-8 trial
Shota Takahashi
Real-world effectiveness of ravelinib in CML after two or more tyrosine kinase inhibitors: a multicenter multinational cohort
Álvaro Moreno
Treatment patterns and survival in patients with massive hemorrhage: real-world data from the Italian transfusion registry
Elizabeth Carter
Multi-omic characterization of lineage priming in early progenitors in healthy donors
Oliver Walker
Prognostic value of FLT3-ITD allelic ratio in adults with newly diagnosed AML receiving intensive induction: results from BEACON-2
Sabine Beck
Targeting epigenetic memory after infection in normal and malignant hematopoiesis: preclinical evidence
Ayumi Yamada
Prognostic value of frailty scores in long-term survivors of childhood leukemia: results from SUMMIT-1
Andreas Zimmermann
Health-related quality of life in CML after two or more tyrosine kinase inhibitors: a prospective french study
Emily Murray
Nelbrutinib plus ibrutinib in CLL with del(17p) or TP53 mutation: phase 3 results of the VIKING-9 trial
Anna Grasso
Long-term outcomes of relapsed CLL after covalent BTK inhibitors treated with acalabrutinib: a Dutch registry study of 412 patients
Yan He
Vedotalimab plus post-transplant cyclophosphamide in older recipients of reduced-intensity conditioning: phase 1 results of the VALOR-5 trial
Richard Hughes
Long-term outcomes of chronic-phase CML in deep molecular response treated with imatinib: a Spanish registry study of 87 patients
Maya Carmeli
Targeting neutrophil extracellular traps in thrombosis in bleeding and thrombotic disorders: preclinical evidence
Kenji Takahashi
Efficacy and safety of abelorimab in patients with antiphospholipid syndrome: primary analysis of the phase 1 ZENITH-6 study
Romain Morel
Sabrelimab versus erythropoiesis-stimulating agents in higher-risk MDS (SAGA-4): a randomized phase 2 trial
Johanna Krause
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Zeynep Doğan
Rusperatide plus ropeginterferon alfa-2b in JAK inhibitor-naive myelofibrosis: phase 1 results of the BEACON-6 trial
Chen Wang
Real-world effectiveness of brexalucel in peripheral T-cell lymphoma: a multicenter italian cohort
Sophie Ward
Real-world effectiveness of linzotamab in triple-class exposed myeloma: a multicenter nordic cohort
Steven Thompson
Concivumab plus low-molecular-weight heparin in cancer-associated venous thromboembolism: randomized phase 3 results of the TRIDENT-1 trial
Fernanda Ferreira
Efficacy and safety of itovazumab in older recipients of reduced-intensity conditioning: primary analysis of the phase 1b/2 ALTITUDE-2 study
Amelia Brown
Treatment patterns and survival in previously untreated follicular lymphoma: real-world data from the international lymphoma registry
Fabio Caruso
Real-world effectiveness of navolatib in JAK inhibitor-naive myelofibrosis: a multicenter french cohort
Moritz Frank
Mitazovat plus iron chelation in patients with iron deficiency anemia: phase 3 results of the AURORA-8 trial
Aurélie Robert
Prognostic value of fetal hemoglobin in adults with sickle cell disease: results from VIKING-4
Laura Schneider
Prognostic value of ferritin in donors in patients with massive hemorrhage: results from POLARIS-4
Paola Costa
Single-cell profiling reveals lineage switch after CD19-directed therapy in acute lymphoblastic leukemia (ALL)
Daniel Schröder
Marsatimab versus emicizumab prophylaxis in adults with immune thrombocytopenia (TRIDENT-6): a randomized phase 3 trial
Qing Liu
Cold-stored platelets versus patient blood management in patients with massive hemorrhage (SAGA-3): a phase 1b/2 trial
João Fernandes
Real-world effectiveness of itovazumab in haploidentical transplant recipients: a multicenter nordic cohort
Fernando Gil
Efficacy and safety of ibarodomide in triple-class exposed myeloma: primary analysis of the phase 1 MERIDIAN-7 study
Stefan Frank
Validation of a deep-learning cytomorphology model for the diagnosis of myeloid neoplasms across 35 centers
Bin Chen
Long-term outcomes of preterm neonates treated with patient blood management: a French registry study of 812 patients
Javier Molina
Treatment patterns and survival in higher-risk MDS: real-world data from the international MDS registry
Étienne Moreau
Efficacy and safety of luspaterpin in MDS with SF3B1 mutation: primary analysis of the phase 3 VALOR-5 study
Pedro Ferreira
Real-world effectiveness of pathogen-reduced platelets in preterm neonates: a multicenter international cohort
Ali Saad
Treatment patterns and survival in high-risk smoldering myeloma: real-world data from the European myeloma registry
Jessica Campbell
Long-term outcomes of MDS with SF3B1 mutation treated with azacitidine: a Spanish registry study of 586 patients
Nicole Roberts
Real-world effectiveness of tovaclax in CLL with del(17p) or TP53 mutation: a multicenter international cohort
Sophie Henry
Targeting CD20 antigen loss after bispecifics in lymphoma: preclinical evidence
Florian Frank
A large language model assistant compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Youssef Mansour
Momavotinib plus ropeginterferon alfa-2b in essential thrombocythemia: phase 3 results of the ATLAS-1 trial
Lena Friedrich
Prognostic value of hemoglobin response in pyruvate kinase deficiency: results from ALTITUDE-1
Martin Scholz
A large language model assistant compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Marcin Kowalczyk
Treatment patterns and survival in patients receiving CD19-directed CAR T-cell therapy: real-world data from the international cell therapy registry
Ida Olsen
Lovotigene autotemcel plus lymphodepletion with fludarabine and cyclophosphamide in transfusion-dependent beta-thalassemia: randomized phase 2 results of the SUMMIT-2 trial
Petr Kučera
Prognostic value of FLT3-ITD allelic ratio in adults with newly diagnosed AML receiving intensive induction: results from SUMMIT-1
Yan Zhao
Efficacy and safety of orvematinib in chronic-phase CML in deep molecular response: primary analysis of the phase 3 TRIDENT-6 study
David Sánchez
Multi-omic characterization of lineage priming in early progenitors in human cord blood
Rocío Vázquez
Efficacy and safety of tovaclax in relapsed CLL after covalent BTK inhibitors: primary analysis of the phase 2 NORDLYS-7 study
Jorge Castro
Single-cell profiling reveals neutrophil extracellular traps in thrombosis in bleeding and thrombotic disorders
Óscar Morales
Multi-omic characterization of red cell storage lesion in preterm neonates
Johanna Roth
Glovutamab versus bendamustine and rituximab in classic Hodgkin lymphoma (CASCADE-8): a randomized phase 2 trial
Péter Horváth
Single-cell profiling reveals clonal evolution at relapse in acute myeloid leukemia (AML)
Keiko Yamamoto
Treatment patterns and survival in essential thrombocythemia: real-world data from the Spanish MPN registry
Christopher Roberts
Zelvudocel plus blinatumomab in T-cell ALL: randomized phase 3 results of the HORIZON-1 trial
Arjun Banerjee
Single-cell profiling reveals steroid resistance pathways in acute lymphoblastic leukemia (ALL)
Eleanor Campbell
D-dimer predicts outcome in cancer-associated venous thromboembolism
Francesco Parisi
Ponavatinib plus tyrosine kinase inhibitors in children with high-risk B-cell ALL: randomized phase 3 results of the CORONA-6 trial
Lotte de Vries
A deep-learning cytomorphology model compared with standard diagnostic workup on routine blood counts in primary care: a prospective multicenter evaluation
Ayumi Inoue
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Omer Barak
Nk-501 versus lymphodepletion with fludarabine and cyclophosphamide in patients receiving CD19-directed CAR T-cell therapy (PRISM-6): a randomized phase 2 trial
Nicole Green
Multi-omic characterization of lineage priming in early progenitors in aged mice
Esther Bakker
Efficacy and safety of letermovir in patients with invasive fungal infections: primary analysis of the phase 2 ECLIPSE-1 study
Andreea Popescu
Real-world effectiveness of nelbrutinib in older patients with CLL and comorbidities: a multicenter italian cohort
Vasiliki Karagiannis
Pirvabrutinib plus fixed-duration venetoclax in older patients with CLL and comorbidities: phase 2 results of the POLARIS-8 trial
Stephanie Harris
Targeting steroid resistance pathways in acute lymphoblastic leukemia (ALL): preclinical evidence
Moritz Huber
Real-world effectiveness of tamirodene in lower-risk MDS with transfusion-dependent anemia: a multicenter nordic cohort
Sanne Dekker
Long-term outcomes of patients with invasive fungal infections treated with standard supportive care: a Spanish registry study of 1240 patients
Hui Wang
Prognostic value of donor-specific antibodies in adults undergoing allogeneic stem cell transplantation for AML: results from AURORA-2
Cristina Vázquez
Real-world effectiveness of letermovir in patients with invasive fungal infections: a multicenter nordic cohort
Sara Russo
Efficacy and safety of rusperatide in myelofibrosis after ruxolitinib failure: primary analysis of the phase 1b/2 AURORA-9 study
Athanasios Papageorgiou
Ravelinib plus imatinib in chronic-phase CML in deep molecular response: randomized phase 3 results of the ATLAS-3 trial
Michael Friedrich
Prognostic value of CAR T expansion kinetics in recipients of allogeneic off-the-shelf CAR NK cells: results from ZENITH-7
Daniel Taylor
A deep-learning cytomorphology model compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Chiara Lombardo
Pet-negative complete metabolic response predicts outcome in previously untreated follicular lymphoma
Wolfgang Lorenz
Prognostic value of platelet response in hemophilia B: results from PRISM-7
Christine Nelson
Targeting BCR signalling rewiring in chronic lymphocytic leukemia (CLL): preclinical evidence
Helen Hill
Prognostic value of TET2 and DNMT3A clones in aged mice: results from POLARIS-8
Giovanni Grasso
Targeting tumour microenvironment remodelling in lymphoma: preclinical evidence
Claudio Ferri
Real-world effectiveness of corvalimab in adolescents and young adults with ALL: a multicenter french cohort
Judith van der Linden
Zelvudocel versus blinatumomab in T-cell ALL (ZENITH-4): a randomized phase 2 trial
Robert Williams
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Maximilian Schulz
Cold-stored platelets plus restrictive transfusion thresholds in patients with massive hemorrhage: randomized phase 2 results of the AURORA-2 trial
Joost Meijer
Health-related quality of life in blood donors: a prospective multinational study
Clément Moreau
Long-term outcomes of CLL with del(17p) or TP53 mutation treated with ibrutinib: a Italian registry study of 231 patients
Davide Ferrara
Prognostic value of cell-of-origin subtype in primary CNS lymphoma: results from POLARIS-1
Samuel Williams
Real-world effectiveness of belosarib in older recipients of reduced-intensity conditioning: a multicenter spanish cohort
Akiko Ito
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Gustavo Costa
Lovotigene autotemcel versus busulfan myeloablation in patients receiving CD19-directed CAR T-cell therapy (VIKING-3): a phase 2 trial
Aleksandra Jankowski
Mitazovat plus chronic transfusion in children with sickle cell disease in sub-Saharan Africa: phase 2 results of the VALOR-8 trial
Diego Gil
Treatment patterns and survival in chronic-phase CML in deep molecular response: real-world data from the German CML registry
Laura Winkler
Multi-omic characterization of red cell membrane dysfunction in pyruvate kinase deficiency
Maria Berg
Prognostic value of fetal hemoglobin in children with sickle cell disease in sub-Saharan Africa: results from TRIDENT-5
Miguel Moreno
Ibarodomide plus daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering myeloma: randomized phase 2 results of the BEACON-6 trial
Elina Lehtinen
Real-world effectiveness of lirafenib in NPM1-mutated AML: a multicenter italian cohort
Jonathan Morris
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Merve Özkan
Health-related quality of life in relapsed CLL after covalent BTK inhibitors: a prospective nordic study
Sébastien David
Abl1 kinase domain mutations predicts outcome in CML after two or more tyrosine kinase inhibitors
Ivana Stojanović
Osiverol plus iron chelation in pyruvate kinase deficiency: randomized phase 2 results of the VIKING-3 trial
Liang Ma
Efficacy and safety of abelorimab in patients with antiphospholipid syndrome: primary analysis of the phase 1b/2 ALTITUDE-2 study
Ilaria Vitale
Prognostic value of ABL1 kinase domain mutations in chronic-phase CML in deep molecular response: results from ALTITUDE-2
Thiago Ribeiro
Long-term outcomes of blood donors treated with restrictive transfusion thresholds: a Nordic registry study of 586 patients
Li Li
Tovaclax plus ibrutinib in older patients with CLL and comorbidities: phase 1b/2 results of the CASCADE-9 trial
Claudia Schulz
Undetectable mrd predicts outcome in relapsed CLL after covalent BTK inhibitors
Charlotte Wright
Pathogen-reduced platelets plus restrictive transfusion thresholds in blood donors: phase 3 results of the CORONA-3 trial
Diego Blanco
Prognostic value of CAR T expansion kinetics in patients with sickle cell disease treated with gene editing: results from POLARIS-7
Franziska Müller
Real-world effectiveness of talvetamab in relapsed/refractory multiple myeloma after three prior lines: a multicenter french cohort
Emil Lindström
Ascavinib versus dasatinib in CML after two or more tyrosine kinase inhibitors (SAGA-1): a phase 1 trial
Dina Nasser
Health-related quality of life in lower-risk MDS with transfusion-dependent anemia: a prospective german study
Andrea Vogel
Efficacy and safety of talvetamab in newly diagnosed transplant-eligible multiple myeloma: primary analysis of the phase 3 SUMMIT-2 study
Camilla Rasmussen
Single-cell profiling reveals transfusion-related immunomodulation in transfusion practice
Shota Shimizu
Prognostic value of BCR::ABL1 transcript levels in newly diagnosed chronic-phase CML: results from VALOR-1
Jorge Muñoz
Efficacy and safety of lirafenib in relapsed or refractory FLT3-mutated AML: primary analysis of the randomized phase 3 VALOR-8 study
Yong Lin
Long-term outcomes of patients receiving CD19-directed CAR T-cell therapy treated with lymphodepletion with fludarabine and cyclophosphamide: a German registry study of 812 patients
Christopher Carter
Prognostic value of TP53 status in classic Hodgkin lymphoma: results from ATLAS-5
Nour Haddad
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Andrei Smirnov
Treatment patterns and survival in high-risk smoldering myeloma: real-world data from the Dutch myeloma registry
Alessandro Longo
Multi-omic characterization of gut epithelial injury in GVHD in patients with steroid-refractory acute graft-versus-host disease
Émilie François
Targeting steroid resistance pathways in acute lymphoblastic leukemia (ALL): preclinical evidence
Esther de Jong
Prognostic value of Ph-like signatures in children with high-risk B-cell ALL: results from VALOR-5
Ananya Mukherjee
Health-related quality of life in peripheral T-cell lymphoma: a prospective nordic study
Shota Nakamura
Treatment patterns and survival in people with severe hemophilia A: real-world data from the French hemostasis registry
Rocío Fernández
Real-world effectiveness of cold-stored platelets in patients undergoing cardiac surgery: a multicenter french cohort
Ali Najjar
Talvetamab versus teclistamab in triple-class exposed myeloma (ARCTIC-3): a randomized phase 3 trial
Neta Ben-David
Efficacy and safety of NK-501 in recipients of allogeneic off-the-shelf CAR NK cells: primary analysis of the phase 2 ALTITUDE-7 study
Eric Edwards
Efficacy and safety of quelcitamab in newly diagnosed AML patients ineligible for intensive chemotherapy: primary analysis of the phase 1b/2 POLARIS-8 study
Fatima Mansour
Efficacy and safety of cold-stored platelets in preterm neonates: primary analysis of the phase 2 NORDLYS-4 study
George Baker
Whole blood versus patient blood management in preterm neonates (HELIOS-6): a phase 2 trial
Alexander Kaiser
Talvetamab versus carfilzomib and dexamethasone in high-risk smoldering myeloma (ECLIPSE-5): a phase 2 trial
Roberta Russo
Rilvabrutinib versus thrombopoietin receptor agonists in adults with immune thrombocytopenia (ALTITUDE-9): a randomized phase 3 trial
Isabelle Morel
Efficacy and safety of ibrexitamab in children with high-risk B-cell ALL: primary analysis of the phase 1 PRISM-5 study
Christos Alexiou
Efficacy and safety of pelarisib in essential thrombocythemia: primary analysis of the randomized phase 2 PRISM-8 study
Charlotte Jones
Health-related quality of life in lower-risk MDS with transfusion-dependent anemia: a prospective spanish study
Cristina Lombardi
Treatment patterns and survival in patients with antiphospholipid syndrome: real-world data from the Italian hemostasis registry
Lorenzo Marini
Ascavinib plus nilotinib in CML after two or more tyrosine kinase inhibitors: randomized phase 3 results of the HELIOS-2 trial
Ali Aziz
Navolatib plus ropeginterferon alfa-2b in myelofibrosis after ruxolitinib failure: phase 2 results of the ALTITUDE-1 trial
Jae-won Lee
Real-world effectiveness of cold-stored platelets in patients undergoing cardiac surgery: a multicenter german cohort
Iván Gil
Multi-omic characterization of immune effector cell-associated neurotoxicity in recipients of allogeneic off-the-shelf CAR NK cells
Cristina López
Momavotinib plus hydroxyurea in essential thrombocythemia: randomized phase 3 results of the HORIZON-8 trial
Ashley Mitchell
Prognostic value of IKZF1 deletions in children with high-risk B-cell ALL: results from HORIZON-2
Stefanie Lehmann
Single-cell profiling reveals gut epithelial injury in GVHD in allogeneic stem cell transplantation
Reem Nasser
Long-term outcomes of treatment-naive CLL treated with ibrutinib: a Italian registry study of 304 patients
Felipe Alves
Orvematinib plus nilotinib in newly diagnosed chronic-phase CML: phase 3 results of the VIKING-6 trial
Juan Lin
Real-world effectiveness of vedotalimab in adults undergoing allogeneic stem cell transplantation for AML: a multicenter german cohort
Javier Romero
Bcr::abl1 transcript levels predicts outcome in CML after two or more tyrosine kinase inhibitors
Antonio Parisi
Targeting financial toxicity in hematologic malignancies: preclinical evidence
Jian Wu
Treatment patterns and survival in relapsed/refractory multiple myeloma after three prior lines: real-world data from the Spanish myeloma registry
Roberto Ferraro
Long-term outcomes of relapsed CLL after covalent BTK inhibitors treated with fixed-duration venetoclax: a multinational registry study of 586 patients
Carlos Sanz
Prognostic value of donor-specific antibodies in patients with steroid-refractory acute graft-versus-host disease: results from ALTITUDE-7
Balázs Kiss
Treatment patterns and survival in patients receiving CAR T-cell therapy: real-world data from the French supportive care registry
Teemu Turunen
Itovazumab plus tacrolimus and methotrexate in older recipients of reduced-intensity conditioning: randomized phase 2 results of the SAGA-9 trial
Ana Suárez
Prognostic value of vector copy number in recipients of allogeneic off-the-shelf CAR NK cells: results from ALTITUDE-6
Ruth Avraham
Tovaclax versus ibrutinib in treatment-naive CLL (HELIOS-3): a randomized phase 2 trial
Luca Galli
Real-world effectiveness of lisarnetamab in peripheral T-cell lymphoma: a multicenter french cohort
Daniel Neumann
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Frank Fuchs
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Sara Romano
Real-world effectiveness of epretamab in mantle cell lymphoma after BTK inhibitor failure: a multicenter dutch cohort
Christian Meyer
Prognostic value of IKZF1 deletions in children with high-risk B-cell ALL: results from ALTITUDE-5
Riccardo Conti
Pathogen-reduced platelets plus restrictive transfusion thresholds in patients undergoing cardiac surgery: phase 1 results of the SUMMIT-8 trial
Jonas Jung
Real-world effectiveness of NK-501 in patients receiving CD19-directed CAR T-cell therapy: a multicenter german cohort
Joseph Campbell
Real-world effectiveness of belosarib in patients with steroid-refractory acute graft-versus-host disease: a multicenter international cohort
Iris Brouwer
Multi-omic characterization of lineage priming in early progenitors in patients with clonal hematopoiesis of indeterminate potential
Margaux Dupont
Efficacy and safety of vedotalimab in adults undergoing allogeneic stem cell transplantation for AML: primary analysis of the randomized phase 3 TRIDENT-8 study
Christos Papadopoulos
Olorofim plus standard supportive care in long-term survivors of childhood leukemia: phase 1b/2 results of the SUMMIT-2 trial
Alexander Friedrich
Hsc quiescence markers predicts outcome in human cord blood
Jeroen Dekker
A deep-learning cytomorphology model compared with expert morphological review on multicenter flow cytometry datasets: a prospective multicenter evaluation
Jennifer Martin
Efficacy and safety of osiverol in children with sickle cell disease in sub-Saharan Africa: primary analysis of the phase 1 VIKING-3 study
Roberto Marino
Pathogen-reduced platelets versus restrictive transfusion thresholds in patients undergoing cardiac surgery (CASCADE-9): a phase 2 trial
Sara Moretti
Real-world effectiveness of whole blood in blood donors: a multicenter british cohort
Patrícia Moreira
Real-world effectiveness of osiverol in patients with iron deficiency anemia: a multicenter french cohort
Olivier Garnier
Health-related quality of life in newly diagnosed chronic-phase CML: a prospective multinational study
Lena Roth
A large language model assistant compared with standard diagnostic workup on routine blood counts in primary care: a prospective multicenter evaluation
Péter Tóth
Prognostic value of platelet count increment in patients with massive hemorrhage: results from SUMMIT-4
Carolin Schröder
Health-related quality of life in haploidentical transplant recipients: a prospective german study
Magnus Lindström
Tamirodene versus azacitidine in lower-risk MDS with transfusion-dependent anemia (VALOR-8): a randomized phase 2 trial
Martina Bianchi
Long-term outcomes of haploidentical transplant recipients treated with anti-thymocyte globulin: a French registry study of 412 patients
Charlotte Garcia
Long-term outcomes of patients receiving CAR T-cell therapy treated with standard supportive care: a British registry study of 64 patients
Luca Martini
Belosarib plus post-transplant cyclophosphamide in older recipients of reduced-intensity conditioning: phase 1b/2 results of the SAGA-1 trial
Helena Larsson
Donor-specific antibodies predicts outcome in patients with steroid-refractory acute graft-versus-host disease
Florian Wolf
Odrolimab plus bendamustine and rituximab in mantle cell lymphoma after BTK inhibitor failure: randomized phase 3 results of the POLARIS-2 trial
Marta Ramírez
Odrolimab plus CAR T-cell therapy in peripheral T-cell lymphoma: phase 3 results of the TRIDENT-8 trial
Romain Dubois
Exacatogene autotemcel plus lymphodepletion with fludarabine and cyclophosphamide in patients receiving CD19-directed CAR T-cell therapy: phase 2 results of the ARCTIC-3 trial
Marieke de Jong
Real-world effectiveness of cold-stored platelets in blood donors: a multicenter spanish cohort
Julia Berger
Real-world effectiveness of concivumab in hemophilia B: a multicenter french cohort
Scott Harris
Treatment patterns and survival in relapsed/refractory multiple myeloma after three prior lines: real-world data from the Dutch myeloma registry
Mads Madsen
Treatment patterns and survival in adults with sickle cell disease: real-world data from the Spanish SCD registry
Riccardo Russo
Validation of a deep-learning cytomorphology model for early detection of acute leukemia across 57 centers
Tereza Veselý
A deep-learning cytomorphology model compared with standard diagnostic workup on patients with suspected myeloid neoplasms: a prospective multicenter evaluation
Malin Nilsson
Real-world effectiveness of itovazumab in haploidentical transplant recipients: a multicenter international cohort
Daniel Domínguez
Orvematinib plus nilotinib in newly diagnosed chronic-phase CML: phase 1b/2 results of the MERIDIAN-7 trial
Ryan Jackson
Whole blood plus patient blood management in preterm neonates: phase 1b/2 results of the VIKING-1 trial
Pauline Vincent
Treatment patterns and survival in polycythemia vera: real-world data from the European MPN registry
Megan Thomas
A deep-learning cytomorphology model compared with expert morphological review on patients with suspected myeloid neoplasms: a prospective multicenter evaluation
Panagiotis Papadakis
Health-related quality of life in lower-risk MDS with transfusion-dependent anemia: a prospective french study
Jakub Kowalski
Sabrelimab plus erythropoiesis-stimulating agents in therapy-related MDS: randomized phase 2 results of the HORIZON-3 trial
Riccardo Lombardo
Whole blood plus restrictive transfusion thresholds in patients undergoing cardiac surgery: randomized phase 2 results of the SUMMIT-3 trial
Daniel Young
Real-world effectiveness of concivumab in patients with antiphospholipid syndrome: a multicenter european cohort
William Green
Health-related quality of life in patients with iron deficiency anemia: a prospective german study
David Jiménez
Jak2 v617f allele burden predicts outcome in JAK inhibitor-naive myelofibrosis
Jonathan Ward
Validation of a deep-learning cytomorphology model for the diagnosis of myeloid neoplasms across 62 centers
Alessandra Moretti
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Larissa Carvalho
Targeting alloreactive T-cell expansion in allogeneic stem cell transplantation: preclinical evidence
Sara De Luca
Real-world effectiveness of a digital symptom-monitoring program in older patients with hematologic cancers: a multicenter multinational cohort
Andreas Schneider
Olorofim plus standard supportive care in patients with invasive fungal infections: phase 1b/2 results of the VIKING-6 trial
Claire Blanc
Validation of a large language model assistant for automated classification of bone marrow cells across 30 centers
Piotr Kozłowski
Prognostic value of IPSS-M risk category in higher-risk MDS: results from SAGA-7
Manuel Serrano
Real-world effectiveness of tozarinib in adults with newly diagnosed AML receiving intensive induction: a multicenter multinational cohort
Joost Janssen
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Eric Jones
Real-world effectiveness of pelarisib in myelofibrosis after ruxolitinib failure: a multicenter german cohort
Miguel Martins
Zelvudocel plus lymphodepletion with fludarabine and cyclophosphamide in patients receiving CD19-directed CAR T-cell therapy: phase 3 results of the VIKING-8 trial
Robert Murray
Ponavatinib versus blinatumomab in relapsed B-cell precursor ALL (VIKING-4): a phase 1b/2 trial
Thomas Patel
Efficacy and safety of vedotalimab in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the randomized phase 3 HORIZON-9 study
Matteo De Luca
Multi-omic characterization of clonal evolution under BCMA pressure in triple-class exposed myeloma
Matteo Rossi
Real-world effectiveness of SVX-12 in older patients with CLL and comorbidities: a multicenter british cohort
Johannes Huber
Real-world effectiveness of orvematinib in CML after two or more tyrosine kinase inhibitors: a multicenter french cohort
Mustafa Kara
Itovazumab plus anti-thymocyte globulin in patients with steroid-refractory acute graft-versus-host disease: randomized phase 3 results of the NORDLYS-9 trial
Karolina Nowak
Multi-omic characterization of epigenetic memory after infection in human cord blood
Matteo Martinelli
Prognostic value of vaso-occlusive crisis rate in adults with sickle cell disease: results from HORIZON-3
Élodie Dubois
Health-related quality of life in older patients with hematologic cancers: a prospective european study
Kimberly Clark
Efficacy and safety of tamirodene in higher-risk MDS: primary analysis of the randomized phase 3 ECLIPSE-4 study
Daisuke Yamaguchi
Prognostic value of ferritin in donors in patients with massive hemorrhage: results from CORONA-8
Marija Jurić
Health-related quality of life in adults with Philadelphia chromosome-positive ALL: a prospective nordic study
Ida Johansson
Real-world effectiveness of quelcitamab in AML in first complete remission: a multicenter dutch cohort
Marta Gentile
Treatment patterns and survival in preterm neonates: real-world data from the British transfusion registry
Katharina Günther
Efficacy and safety of olorofim in patients receiving CAR T-cell therapy: primary analysis of the phase 3 HORIZON-1 study
Raquel Delgado
Efficacy and safety of zelvudocel in relapsed B-cell precursor ALL: primary analysis of the phase 2 MERIDIAN-6 study
Signe Møller
Prognostic value of IGHV mutational status in fit patients with untreated CLL: results from ZENITH-5
Marie Roth
Prognostic value of annualized bleeding rate in hemophilia B: results from PRISM-6
Liang Huang
Mitazovat plus iron chelation in patients with iron deficiency anemia: phase 2 results of the ARCTIC-8 trial
Franziska Baumann
A large language model assistant compared with standard diagnostic workup on patients with suspected myeloid neoplasms: a prospective multicenter evaluation
Alexander Becker
Nelbrutinib versus ibrutinib in CLL with del(17p) or TP53 mutation (CASCADE-3): a randomized phase 3 trial
María Ramos
Efficacy and safety of letermovir in older patients with hematologic cancers: primary analysis of the randomized phase 2 TRIDENT-3 study
Omar Khoury
Multi-omic characterization of tissue factor pathway regulation in hemophilia B
Emily Phillips
Long-term outcomes of preterm neonates treated with restrictive transfusion thresholds: a German registry study of 64 patients
Philipp Jung
Long-term outcomes of mantle cell lymphoma after BTK inhibitor failure treated with Pola-R-CHP: a French registry study of 87 patients
Jonathan Hill
Treatment patterns and survival in older patients with CLL and comorbidities: real-world data from the Italian CLL registry
Georgia Alexiou
Marsatimab versus direct oral anticoagulants in people with severe hemophilia A (POLARIS-5): a randomized phase 2 trial
Kari Hansen
Real-world effectiveness of whole blood in blood donors: a multicenter german cohort
Rik Dijkstra
Prognostic value of JAK2 V617F allele burden in myelofibrosis with anemia: results from HORIZON-5
Katherine Walker
Inclazumab versus hydroxyurea in non-transfusion-dependent beta-thalassemia (ALTITUDE-6): a phase 1b/2 trial
Hannah Bennett
Prognostic value of clonal hematopoiesis in AML in first complete remission: results from CORONA-3
Eline de Haan
Long-term outcomes of chronic-phase CML in deep molecular response treated with dasatinib: a German registry study of 812 patients
Anna Pettersson
Ibrexitamab plus blinatumomab in T-cell ALL: phase 3 results of the CASCADE-5 trial
Mihai Popescu
Health-related quality of life in cancer-associated venous thromboembolism: a prospective french study
Lars Gustafsson
Rusperatide versus ropeginterferon alfa-2b in JAK inhibitor-naive myelofibrosis (CORONA-7): a phase 1 trial
Eun-ji Jung
Prognostic value of hepcidin levels in children with sickle cell disease in sub-Saharan Africa: results from TRIDENT-3
Roberta Marchetti
Real-world effectiveness of ascavinib in newly diagnosed chronic-phase CML: a multicenter spanish cohort
Renata Silva
Real-world effectiveness of linzotamab in triple-class exposed myeloma: a multicenter international cohort
Arjen de Haan
Prognostic value of inflammatory memory in aged mice: results from SAGA-3
Ewa Kaczmarek
Multi-omic characterization of clonal evolution at relapse in older adults with secondary AML
Pablo López
Efficacy and safety of mitazovat in pyruvate kinase deficiency: primary analysis of the phase 1 CORONA-3 study
Adrián Hernández
Long-term outcomes of relapsed or refractory large B-cell lymphoma treated with bendamustine and rituximab: a Dutch registry study of 146 patients
Oliver Evans
Alloimmunization predicts outcome in patients undergoing cardiac surgery
Chloé Roux
Treatment patterns and survival in CLL with del(17p) or TP53 mutation: real-world data from the Dutch CLL registry
Maximilian Bauer
Real-world effectiveness of pathogen-reduced platelets in patients undergoing cardiac surgery: a multicenter dutch cohort
Koen Janssen
Prognostic value of inflammatory memory in human cord blood: results from ARCTIC-4
Vincent Laurent
Sabrelimab versus luspatercept in therapy-related MDS (POLARIS-9): a phase 1b/2 trial
Noam Goldberg
Long-term outcomes of haploidentical transplant recipients treated with tacrolimus and methotrexate: a Spanish registry study of 812 patients
Daan Visser
Efficacy and safety of brexalucel in previously untreated follicular lymphoma: primary analysis of the phase 3 MERIDIAN-9 study
Giuseppe Rizzo
Health-related quality of life in NPM1-mutated AML: a prospective german study
Markus Köhler
Real-world effectiveness of efactocog beta in patients with antiphospholipid syndrome: a multicenter german cohort
Laura De Luca
Health-related quality of life in JAK inhibitor-naive myelofibrosis: a prospective international study
Maria Salonen
A federated learning platform compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Bas van Leeuwen
Momavotinib plus ruxolitinib in essential thrombocythemia: phase 2 results of the TRIDENT-9 trial
Lejla Popović
Exacatogene autotemcel versus lymphodepletion with fludarabine and cyclophosphamide in recipients of allogeneic off-the-shelf CAR NK cells (HELIOS-9): a phase 2 trial
Gizem Kılıç
Validation of a large language model assistant for early detection of acute leukemia across 14 centers
Hugo Faure
Telvostat versus azacitidine in higher-risk MDS (ARCTIC-9): a phase 1 trial
Jürgen Lehmann
Validation of a large language model assistant for the diagnosis of myeloid neoplasms across 62 centers
Julia Wilson
Long-term outcomes of myelofibrosis after ruxolitinib failure treated with ropeginterferon alfa-2b: a French registry study of 42 patients
Matteo Lombardo
Real-world effectiveness of tamirodene in therapy-related MDS: a multicenter nordic cohort
Thomas Lewis
Treatment patterns and survival in JAK inhibitor-naive myelofibrosis: real-world data from the Italian MPN registry
Antonio Alonso
Treatment patterns and survival in patients with iron deficiency anemia: real-world data from the international SCD registry
Liang Zhu
Long-term outcomes of patients with steroid-refractory acute graft-versus-host disease treated with post-transplant cyclophosphamide: a Nordic registry study of 812 patients
Mikkel Pedersen
Efficacy and safety of efactocog beta in patients with antiphospholipid syndrome: primary analysis of the phase 1b/2 VALOR-3 study
Patricia González
Targeting epigenetic memory after infection in normal and malignant hematopoiesis: preclinical evidence
Nicole Köhler
Itovazumab plus post-transplant cyclophosphamide in patients with steroid-refractory acute graft-versus-host disease: randomized phase 3 results of the VALOR-2 trial
Giovanni Leone
Anicavocel versus carfilzomib and dexamethasone in high-risk smoldering myeloma (ECLIPSE-2): a phase 1 trial
Alba Díaz
Letermovir versus antifungal prophylaxis in older patients with hematologic cancers (HELIOS-2): a randomized phase 3 trial
Dejan Novak
Frailty scores predicts outcome in older patients with hematologic cancers
João Gomes
Long-term outcomes of adults with newly diagnosed AML receiving intensive induction treated with azacitidine: a Dutch registry study of 42 patients
Alessandra Russo
Validation of a deep-learning cytomorphology model for automated classification of bone marrow cells across 45 centers
Alessandro Marino
Validation of a large language model assistant for early detection of acute leukemia across 49 centers
Laura Moreno
Health-related quality of life in patients with sickle cell disease treated with gene editing: a prospective german study
Mette Andersen
Cold-stored platelets versus patient blood management in patients with massive hemorrhage (HELIOS-1): a randomized phase 2 trial
Riccardo Parisi
Prognostic value of cytokine release syndrome grade in transfusion-dependent beta-thalassemia: results from MERIDIAN-8
Olivier Muller
Rilvabrutinib plus direct oral anticoagulants in hemophilia B: phase 1b/2 results of the TRIDENT-5 trial
Steven Thomas
Treatment patterns and survival in older patients with hematologic cancers: real-world data from the German supportive care registry
Robert Parker
Efficacy and safety of epretamab in previously untreated follicular lymphoma: primary analysis of the phase 2 TRIDENT-6 study
Valentina De Luca
Etapivat versus hydroxyurea in adults with sickle cell disease (NORDLYS-9): a randomized phase 3 trial
Andrea Weiß
Marsatimab plus emicizumab prophylaxis in people with severe hemophilia A: phase 1 results of the POLARIS-3 trial
Francesco Serra
Single-cell profiling reveals steroid resistance pathways in acute lymphoblastic leukemia (ALL)
Agnieszka Mazur
Prognostic value of platelet count increment in blood donors: results from ALTITUDE-1
Chiara Villa
Sf3b1 mutations predicts outcome in MDS with SF3B1 mutation
Lucas Carvalho
Circulating tumor dna predicts outcome in relapsed or refractory large B-cell lymphoma
Eva Novotný
Prognostic value of factor VIII activity in hemophilia B: results from ALTITUDE-2
Silvia Jiménez
A digital symptom-monitoring program versus antifungal prophylaxis in older patients with hematologic cancers (PRISM-1): a phase 1b/2 trial
Laura Santoro
Efficacy and safety of osiverol in non-transfusion-dependent beta-thalassemia: primary analysis of the phase 1 SUMMIT-7 study
David Nelson
Targeting platelet desialylation in bleeding and thrombotic disorders: preclinical evidence
Pablo Martín
Real-world effectiveness of tamirodene in MDS with SF3B1 mutation: a multicenter italian cohort
Eleanor Shaw
Targeting thrombosis in MPN in myeloproliferative neoplasms (MPN): preclinical evidence
Silvia Pérez
Treatment patterns and survival in polycythemia vera: real-world data from the Dutch MPN registry
Carmen Castro
Real-world effectiveness of inclazumab in pyruvate kinase deficiency: a multicenter spanish cohort
Li Xu
Ibrexitamab versus pediatric-inspired chemotherapy in adults with Philadelphia chromosome-positive ALL (TRIDENT-2): a phase 1 trial
Roberta De Luca
Treatment patterns and survival in transfusion-dependent beta-thalassemia: real-world data from the Spanish cell therapy registry
Alexander Hartmann
Patient-reported outcomes predicts outcome in patients receiving CAR T-cell therapy
Sarah Lorenz
Measurable residual disease by flow cytometry predicts outcome in newly diagnosed AML patients ineligible for intensive chemotherapy
Henrik Karlsen
Targeting megakaryocyte-driven fibrosis in myeloproliferative neoplasms (MPN): preclinical evidence
Olof Axelsson
Long-term outcomes of children with sickle cell disease in sub-Saharan Africa treated with iron chelation: a German registry study of 812 patients
María Vázquez
Multi-omic characterization of alloreactive T-cell expansion in adults undergoing allogeneic stem cell transplantation for AML
Marija Pavlović
Targeting leukemic stem cell persistence in acute myeloid leukemia (AML): preclinical evidence
Maarten Brouwer
Whole blood plus restrictive transfusion thresholds in blood donors: phase 1 results of the BEACON-8 trial
Kazuki Sasaki
Efficacy and safety of lirafenib in newly diagnosed AML patients ineligible for intensive chemotherapy: primary analysis of the randomized phase 2 CASCADE-1 study
Yan Liu
Long-term outcomes of myelofibrosis after ruxolitinib failure treated with hydroxyurea: a Spanish registry study of 64 patients
Martijn Jacobs
Long-term outcomes of patients with invasive fungal infections treated with antifungal prophylaxis: a international registry study of 1240 patients
Antonio Ortiz
Real-world effectiveness of lovotigene autotemcel in patients receiving CD19-directed CAR T-cell therapy: a multicenter multinational cohort
Valentina Moretti
Long-term outcomes of long-term survivors of childhood leukemia treated with standard supportive care: a multinational registry study of 87 patients
Davide Grasso
Orvematinib versus dasatinib in chronic-phase CML in deep molecular response (VIKING-6): a randomized phase 2 trial
Matteo Vitale
Single-cell profiling reveals CAR T-cell exhaustion in gene and cell therapy
Aikaterini Christodoulou
High-risk cytogenetics predicts outcome in AL amyloidosis
Kevin Edwards
Targeting endothelial activation in hemoglobinopathies: preclinical evidence
Chiara Gallo
Efficacy and safety of whole blood in blood donors: primary analysis of the phase 1 AURORA-8 study
Lauren Wilson
Multi-omic characterization of steroid resistance pathways in adults with Philadelphia chromosome-positive ALL
Adrián Torres
Targeting quiescent CML stem cells in chronic myeloid leukemia (CML): preclinical evidence
Ida Knudsen
Anicavocel plus teclistamab in triple-class exposed myeloma: randomized phase 2 results of the VALOR-4 trial
Maximilian Lange
Targeting ineffective erythropoiesis in myelodysplastic syndromes (MDS): preclinical evidence
Marta De Santis
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Florian Werner
Efficacy and safety of quelcitamab in adults with newly diagnosed AML receiving intensive induction: primary analysis of the phase 3 VALOR-6 study
Klaus Möller
Long-term outcomes of haploidentical transplant recipients treated with post-transplant cyclophosphamide: a multinational registry study of 586 patients
Attila Kovács
Etapivat plus iron chelation in pyruvate kinase deficiency: phase 1 results of the VIKING-2 trial
Marek Piotrowski
Real-world effectiveness of mitazovat in patients with iron deficiency anemia: a multicenter italian cohort
Wouter de Groot
A large language model assistant compared with expert morphological review on multicenter flow cytometry datasets: a prospective multicenter evaluation
Joshua Campbell
Real-world effectiveness of ravelinib in CML after two or more tyrosine kinase inhibitors: a multicenter international cohort
Juan Hu
Health-related quality of life in essential thrombocythemia: a prospective french study
Sarah Fuchs
Efficacy and safety of lisarnetamab in peripheral T-cell lymphoma: primary analysis of the randomized phase 2 HORIZON-7 study
Sophie François
Efficacy and safety of pirvabrutinib in treatment-naive CLL: primary analysis of the phase 2 CASCADE-8 study
Jessica King
Whole blood versus restrictive transfusion thresholds in patients undergoing cardiac surgery (VALOR-2): a randomized phase 3 trial
Hugo Muller
Lirafenib versus decitabine in NPM1-mutated AML (HELIOS-5): a phase 1 trial
Pietro Coppola
Targeting platelet desialylation in bleeding and thrombotic disorders: preclinical evidence
Marija Babić
Multi-omic characterization of inflammasome activation in therapy-related MDS
Felipe Nascimento
Osiverol plus iron chelation in adults with sickle cell disease: phase 2 results of the PRISM-4 trial
Hélène Leroy
Efficacy and safety of luspaterpin in lower-risk MDS with transfusion-dependent anemia: primary analysis of the randomized phase 2 VIKING-6 study
Oliver Hill
Single-cell profiling reveals thrombosis in MPN in myeloproliferative neoplasms (MPN)
Mikkel Johansen
Treatment patterns and survival in adults undergoing allogeneic stem cell transplantation for AML: real-world data from the international allo-HSCT registry
Laura Vitale
Health-related quality of life in blood donors: a prospective dutch study
Petr Veselý
Single-cell profiling reveals alloreactive T-cell expansion in allogeneic stem cell transplantation
Eva Peters
Real-world effectiveness of mitazovat in children with sickle cell disease in sub-Saharan Africa: a multicenter dutch cohort
Tiago Martins
Itovazumab plus anti-thymocyte globulin in patients with steroid-refractory acute graft-versus-host disease: phase 1 results of the VIKING-6 trial
Cristina Coppola
Fetal hemoglobin predicts outcome in pyruvate kinase deficiency
Stephanie Johnson
Prognostic value of TET2 and DNMT3A clones in patients with clonal hematopoiesis of indeterminate potential: results from ALTITUDE-8
Clara Navarro
Real-world effectiveness of ascavinib in CML after two or more tyrosine kinase inhibitors: a multicenter nordic cohort
Alexander Roth
Single-cell profiling reveals leukemia-niche interactions in acute lymphoblastic leukemia (ALL)
Lena Neumann
Prognostic value of FLT3-ITD allelic ratio in relapsed or refractory FLT3-mutated AML: results from ARCTIC-9
Alice Clark
Efficacy and safety of vedotalimab in haploidentical transplant recipients: primary analysis of the phase 1 VALOR-7 study
Brian Edwards
Interferon in polycythemia vera
Clara Vázquez
Myeloproliferative neoplasms: diagnosis and risk assessment
Stefan Krause
Myeloproliferative neoplasms: long-term follow-up
Tarik Hodžić
Cancer-associated thrombosis
Ece Şimşek
Bleeding, thrombosis and platelets: diagnosis and risk assessment
Daniel Brown
Bleeding, thrombosis and platelets: long-term follow-up
Marie Berger
Gene therapy for hemoglobinopathies: access and long-term follow-up
Elena Matei
Gene and cellular therapy: controversies and case discussion
Andreas Fuchs
Gene and cellular therapy: emerging therapies
Julien David
Managing CLL after BTK and BCL-2 inhibitors
Birgit Köhler
Chronic lymphocytic leukemia: first-line treatment
Nuno Oliveira
Chronic lymphocytic leukemia: first-line treatment
Marie Winkler
Survivorship care after hematologic cancer
Fang Sun
Supportive care and quality of life: controversies and case discussion
Klaus Fuchs
Supportive care and quality of life: managing relapse
Fatma Özdemir
Iron deficiency without anemia
Julien Lefebvre
Red cell disorders and hemoglobinopathies: first-line treatment
Julie Garcia
Red cell disorders and hemoglobinopathies: emerging therapies
Neda Moradi
Large language models in clinical hematology
Josip Vuković
Novel technologies and AI: emerging therapies
Lena Pettersson
Novel technologies and AI: diagnosis and risk assessment
Uri Barak
Transplantation in MDS: timing and conditioning
Jelena Jurić
Myelodysplastic syndromes: emerging therapies
Victoria Jackson
Myelodysplastic syndromes: long-term follow-up
Yan Li
Whole blood in trauma
Sophie Wilson
Transfusion medicine: controversies and case discussion
Miriam Schröder
Transfusion medicine: emerging therapies
Fabio Martini
Steroid-refractory GVHD
Sophie Hahn
Stem cell transplantation: diagnosis and risk assessment
Petr Kučera
Stem cell transplantation: controversies and case discussion
Andrew Thompson
Smoldering myeloma: to treat or not to treat
Fernanda Alves
Myeloma and plasma cell disorders: emerging therapies
Olli Nieminen
Myeloma and plasma cell disorders: diagnosis and risk assessment
Anastasia Oikonomou
Clonal hematopoiesis: clinical relevance
Tiago Oliveira
Hematopoiesis and stem cell biology: long-term follow-up
Beatrice Moretti
Hematopoiesis and stem cell biology: first-line treatment
Martin Vogel
Measurable residual disease in AML: what to do with a positive result
Ondřej Horák
Acute myeloid leukemia: first-line treatment
Elena Rossi
Acute myeloid leukemia: controversies and case discussion
Ana Nikolić
Treatment-free remission in CML: who, when and how
Óscar Hernández
Chronic myeloid leukemia: first-line treatment
Lena Schwarz
Chronic myeloid leukemia: controversies and case discussion
Luca Vitale
Acute lymphoblastic leukemia: what is new in the clinic
István Molnár
Acute lymphoblastic leukemia: consensus recommendations
Bram Kok
Acute lymphoblastic leukemia: open questions for research
Lucas Nascimento
Transfusion medicine: open questions for research
Ondřej Svoboda
Transfusion medicine: state of the art
Sem Kok
Transfusion medicine: European registries and collaboration
Pablo Moreno
Bleeding, thrombosis and platelets: open questions for research
Maximilian Krause
Bleeding, thrombosis and platelets: what is new in the clinic
Clara Romero
Bleeding, thrombosis and platelets: state of the art
Jakub Novák
Chronic lymphocytic leukemia: state of the art
Ana Navarro
Chronic lymphocytic leukemia: consensus recommendations
Allison Martin
Chronic lymphocytic leukemia: European registries and collaboration
Paolo Grasso
Chronic myeloid leukemia: state of the art
Lars de Graaf
Chronic myeloid leukemia: European registries and collaboration
Thomas Martin
Chronic myeloid leukemia: what is new in the clinic
Rajesh Kumar
Myeloma and plasma cell disorders: state of the art
Arnaud Henry
Myeloma and plasma cell disorders: what is new in the clinic
Carolin Werner
Myeloma and plasma cell disorders: European registries and collaboration
Theresa Schulz
Lymphoma: regional differences in practice
Jessica Turner
Lymphoma: access to novel therapies
Jing Wang
Lymphoma: perspectives from both sides of the Atlantic
Alexander Braun
Myeloma and plasma cell disorders: access to novel therapies
Alba Molina
Myeloma and plasma cell disorders: regional differences in practice
Matteo Bianco
Myeloma and plasma cell disorders: joint research priorities
Antoine Henry
Myeloproliferative neoplasms: access to novel therapies
Valentina Russo
Myeloproliferative neoplasms: regional differences in practice
Luca Barbieri
Myeloproliferative neoplasms: perspectives from both sides of the Atlantic
Dina Farouk
Acute myeloid leukemia: joint research priorities
Lotte Janssen
Acute myeloid leukemia: perspectives from both sides of the Atlantic
Andrea Werner
Acute myeloid leukemia: access to novel therapies
Carlos Hernández
Opening plenary lecture: Hematology at the frontier of cell and gene therapy
Markus Keller
Plenary lecture: Clonal hematopoiesis, aging and disease
Martin Vogel
Presidential symposium: Curing myeloma — a realistic goal?
Hassan Farouk
Presidential symposium: Precision medicine in acute leukemia
Stefanie Huber
Presidential symposium: Equity of access to advanced therapies in Europe
Martin Kaiser
Best of EHA2025: malignant hematology
Émilie David
Best of EHA2025: non-malignant hematology
Linda Vos
Best of EHA2025: translational research
Luca Vitale
EHA Lifetime Achievement Award Lecture
Matthias Meier
Meet-the-Expert: Chronic myeloid leukemia
Martina Esposito
Meet-the-Expert: Acute lymphoblastic leukemia
Monika Piotrowski
Meet-the-Expert: Transfusion medicine
Céline Bonnet
Meet-the-Expert: Lymphoma
Yong Luo
Meet-the-Expert: Red cell disorders and hemoglobinopathies
Julien David
Meet-the-Expert: Myeloma and plasma cell disorders
Benjamin Lewis
Meet-the-Expert: Chronic lymphocytic leukemia
Lars Holm
Meet-the-Expert: Stem cell transplantation
Richard King
Meet-the-Expert: Gene and cellular therapy
Ana Nikolić +2
Nordheim Pharma Satellite Symposium: Redefining depth of response in multiple myeloma
Wei Yang +2
Corvalis Biotherapeutics Satellite Symposium: Bispecific antibodies across lines of therapy in B-cell lymphoma
Rebecca Mitchell +2
Hemavera Therapeutics Satellite Symposium: Iron, inflammation and anemia: new targets
Joshua Clark +2
Lumora Oncology Satellite Symposium: Targeting menin in acute leukemia
Feng Luo +2
Astelis Bio Satellite Symposium: Gene therapy for hemoglobinopathies in practice
Andrew Thompson +2
Medrion Life Sciences Satellite Symposium: Managing triple-class exposed myeloma
Fatma Özdemir +2
Vireon Biotech Satellite Symposium: Allogeneic CAR T: ready for the clinic?
Daniel Suárez +2
Kaluna Pharma Satellite Symposium: Fixed-duration therapy in CLL
Marcin Kwiatkowski +2
Cyrenna Biologics Satellite Symposium: Hemophilia care beyond factor replacement